



British Pharmacopoeia

British Pharmacopoeia Commission Secretariat
MHRA, 10 South Colonnade
Canary Wharf, London
E14 4PU, United Kingdom
pharmacopoeia.com

Date: 28 May 2024

TO WHOM IT MAY CONCERN

CEFTRIAXONE INJECTION BP 2025

RELATED SUBSTANCES

It has come to our attention that there is an error in the preparation of solution (2) of the Related Substances test for Ceftriaxone Injection. The test states to use ceftriaxone impurity A BPCRS, however this should be ceftriaxone impurity A EPCRS.

Please accept this as a notice of intent to amend the monograph on behalf of the British Pharmacopoeia Commission. This letter is for information only and does not represent a legally-enforceable standard. The revised monograph will be published in a future edition of the British Pharmacopoeia - the current target publication is the BP 2026, which will come into force on 1st January 2026.

If you have any questions concerning this letter, please do not hesitate to contact the British Pharmacopoeia Secretariat (BPCOM@mhra.gov.uk).

Yours faithfully,

MR STEVE HOARE

Secretary & Scientific Director

Email: BPCOM@mhra.gov.uk